ArticleCommunications biology2023
Proton boron capture therapy (PBCT) induces cell death and mitophagy in a heterotopic glioblastoma model.
Article in Communications biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Proton boron capture therapy and neutron capture enhanced proton therapy: a critical review of investigational approaches in proton therapy.Radiological physics and technology · 2026Review
- Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1Pharmaceuticals (Basel, Switzerland) · 2026Article
- Variations among glioblastoma cell lines in boron-mediated enhancement of cell killing by proton beams.Scientific reports · 2025Article
- Polyacrylic Acid-Coated LaBPharmaceutics · 2025Article
- Physiopathological effects of entrance versus distal spread-out Bragg peak on mouse spinal cord neurons.Scientific reports · 2025Article
- Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance.Frontiers in cell and developmental biology · 2025Review
- Proton-boron capture interaction enhances killing of radiation resistant cancer cells.Frontiers in oncology · 2025Article
- Boron Nanoparticle-Enhanced Proton Therapy: Molecular Mechanisms of Tumor Cell Sensitization.Molecules (Basel, Switzerland) · 2024Article
- First independent validation of the proton-boron capture therapy concept.Scientific reports · 2024Article
- Microglia and glioblastoma heterocellular interplay sustains tumour growth and proliferation as an off-target effect of radiotherapy.Cell proliferation · 2024Article
- A ternary model of proton therapy based on boron medium radiosensitization and enhancement paths: a Monte Carlo simulation.Translational cancer research · 2023Article
- Boron Nanoparticle-Enhanced Proton Therapy for Cancer Treatment.Nanomaterials (Basel, Switzerland) · 2023Article
- Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite aggressive therapeutic regimens, glioblastoma (GBM) represents a deadly brain tumor with significant aggressiveness, radioresistance and chemoresistance, leading to dismal prognosis. Hypoxic microenvironment, which characterizes GBM, is associated with reduced therapeutic effectiveness. Moreover, current irradiation approaches are limited by uncertain tumor delineation and severe side effects that comprehensively lead to unsuccessful treatment and to a worsening of the quality of life of GBM patients. Proton beam offers the opportunity of reduced side effects and a depth-dose profile, which, unfortunately, are coupled with low relative biological effectiveness (RBE). The use of radiosensitizing agents, such as boron-containing molecules, enhances proton RBE and increases the effectiveness on proton beam-hit targets. We report a first preclinical evaluation of proton boron capture therapy (PBCT) in a preclinical model of GBM analyzed via μ-positron emission tomography/computed tomography (μPET-CT) assisted live imaging, finding a significant increased therapeutic effectiveness of PBCT versus proton coupled with an increased cell death and mitophagy. Our work supports PBCT and radiosensitizing agents as a scalable strategy to treat GBM exploiting ballistic advances of proton beam and increasing therapeutic effectiveness and quality of life in GBM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.